Patents by Inventor Cheng Lai

Cheng Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibiting GYS2 expression
    Patent number: 12534730
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of GYS2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of GYS2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat glycogen storage diseases (e.g., GSDIa, GSDIII, GSDIV, GSDVI, and GSDIX) and related conditions.
    Type: Grant
    Filed: January 18, 2023
    Date of Patent: January 27, 2026
    Assignee: NOVO NORDISK A/S
    Inventors: Bob D. Brown, Natalie Pursell, Henryk T. Dudek, Cheng Lai
  • METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA
    Publication number: 20240182901
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Application
    Filed: November 29, 2022
    Publication date: June 6, 2024
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Utsav SAXENA, Natalie PURSELL, Cheng LAI, Weimin WANG, Rachel STORR, Naim NAZEF, Boyoung KIM
  • COMPOSITIONS AND METHODS FOR INHIBITING GYS2 EXPRESSION
    Publication number: 20230365974
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of GYS2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of GYS2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat glycogen storage diseases (e.g., GSDIa, GSDIII, GSDIV, GSDVI, and GSDIX) and related conditions.
    Type: Application
    Filed: January 18, 2023
    Publication date: November 16, 2023
    Inventors: Bob D. Brown, Natalie PURSELL, Henryk T. DUDEK, Cheng LAI
  • Methods and compositions for inhibiting expression of LDHA
    Patent number: 11661604
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: May 30, 2023
    Assignee: DICERNA PHARMACEUTICALS, INC.
    Inventors: Bob D. Brown, Henryk T. Dudek, Utsav Saxena, Natalie Pursell, Cheng Lai, Weimin Wang, Rachel Storr, Naim Nazef, Boyoung Kim
  • Methods and compositions for treating bile duct paucity-associated conditions
    Patent number: 11634715
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing CTNNB1 expression, particularly in hepatocytes, for the treatment of bile duct paucity-associated conditions. Disclosed oligonucleotides for the reduction of CTNNB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of CTNNB1 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: April 25, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Natalie Pursell, Cheng Lai
  • Compositions and methods for inhibiting GYS2 expression
    Patent number: 11572562
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of GYS2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of GYS2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat glycogen storage diseases (e.g., GSDIa, GSDIII, GSDIV, GSDVI, and GSDIX) and related conditions.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: February 7, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Natalie Pursell, Henryk T. Dudek, Cheng Lai
  • THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR
    Publication number: 20220396799
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 15, 2022
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Cheng LAI
  • Therapeutic inhibition of lactate dehydrogenase and agents therefor
    Patent number: 11359203
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: June 14, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • Methods and compositions for inhibiting expression of LDHA
    Patent number: 11286488
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: March 29, 2022
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Utsav Saxena, Natalie Pursell, Cheng Lai, Weimin Wang, Rachel Storr, Naim Nazef, Boyoung Kim
  • Therapeutic inhibition of lactate dehydrogenase and agents therefor
    Patent number: 11053502
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: July 6, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR
    Publication number: 20210180068
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactact dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: July 1, 2020
    Publication date: June 17, 2021
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Cheng LAI
  • METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA
    Publication number: 20210062199
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Application
    Filed: September 16, 2020
    Publication date: March 4, 2021
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Utsav SAXENA, Natalie PURSELL, Cheng LAI, Weimin WANG, Rachel STORR, Naim NAZEF, Boyoung KIM
  • COMPOSITIONS AND METHODS FOR INHIBITING GYS2 EXPRESSION
    Publication number: 20210062197
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of GYS2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of GYS2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat glycogen storage diseases (e.g., GSDIa, GSDIII, GSDIV, GSDVI, and GSDIX) and related conditions.
    Type: Application
    Filed: February 15, 2019
    Publication date: March 4, 2021
    Inventors: Bob D. BROWN, Natalie PURSELL, Henryk T. DUDEK, Cheng LAI
  • METHODS AND COMPOSITIONS FOR TREATING BILE DUCT PAUCITY-ASSOCIATED CONDITIONS
    Publication number: 20210010005
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing CTNNB1 expression, particularly in hepatocytes, for the treatment of bile duct paucity-associated conditions. Disclosed oligonucleotides for the reduction of CTNNB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of CTNNB1 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver.
    Type: Application
    Filed: February 15, 2019
    Publication date: January 14, 2021
    Inventors: Natalie PURSELL, Cheng LAI
  • METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA
    Publication number: 20200283775
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Application
    Filed: October 12, 2018
    Publication date: September 10, 2020
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Utsav SAXENA, Natalie PURSELL, Cheng LAI, Weimin WANG, Rachel STORR, Naim NAZEF, Boyoung KIM
  • Therapeutic inhibition of lactate dehydrogenase and agents therefor
    Patent number: 10738311
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactact dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: August 11, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR
    Publication number: 20190323014
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactact dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: March 15, 2019
    Publication date: October 24, 2019
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • Therapeutic inhibition of lactate dehydrogenase and agents therefor
    Patent number: 10351854
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: July 16, 2019
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR
    Publication number: 20170306332
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 26, 2017
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • Reinforced rib of a three-folded umbrella
    Publication number: 20050211283
    Abstract: The invention relates to a reinforced rib of a three-folded umbrella, which is provided with a reinforced rod in the second rib of the frame. The second rib is then to obtain a perfect strength for resisting strong wind and can be effectively used since damage is prevented. The umbrella will be obviously more utilized for use.
    Type: Application
    Filed: March 24, 2004
    Publication date: September 29, 2005
    Inventor: Cheng Lai